Skip to content

Effect of Progesterone Therapy on Traumatic Subarachinoid Haemorrhage on Clinical Outcome and Resistive Vasculer Indices of Middle Cerebral Artery Transcranial Doppler

Effect of Progesterone Therapy in Cases With Traumatic Subarachinoid Haemorrhage on Clinical Outcome and Resistive Vasculer Indices of Middle Cerebral Artery Transcranial Doppler

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04426487
Enrollment
200
Registered
2020-06-11
Start date
2020-06-20
Completion date
2020-10-30
Last updated
2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

Progesterone, Transcranial doppler

Brief summary

Traumatic subarachinoid hemorrhage is associated with serious complications related to mortality . Delayed neuronal ischemia and rebleeding are most common and serious. Progesterone can delay both .

Detailed description

Progesterone is an neurosteroid that can help integrity of blood brain barrier . Traumatic subarachinoid hemorrhage disrupts this blood brain barrier facilitating post traumatic vasospasm and neuronal ischemia. Transcranial doppler can detect cerebral vasoconstriction through resistive vasculer indices

Interventions

DRUGProgesterone

Intramusculer progesterone

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Traumatic subarachinoid hemorrhage

Exclusion criteria

* History of malignency * History of cerebrovasculer stroke * Morbid obese

Design outcomes

Primary

MeasureTime frameDescription
Number of participants suffering neuronal infarction2 monthsTranscranial doppler

Countries

Egypt

Contacts

Primary ContactMina Raouf, MD
drmina2015@gmail.com01015752424

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026